Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Waters Selects Prof. Pauline Rudd for Center of Innovation Program Honors

Published: Friday, April 06, 2012
Last Updated: Thursday, April 05, 2012
Bookmark and Share
Waters-NIBRT partnership advances biopharmaceutical research, characterization and training.

At a ceremony officiated by Minister Sean Sherlock TD, Irish Minister for Research and Innovation, Department of Jobs, Enterprise & Innovation, Waters Corporation welcomed the Irish National Institute for Bioprocessing Research and Training (NIBRT) into its Centers of Innovation Program.

Waters acknowledged NIBRT and the research team under the direction of Prof. Pauline Rudd, Principal Investigator, for her pioneering contribution to the field of glycobiology, a science of growing importance to both biotherapeutics manufacturers and disease research.

“I am honored to be a part of the Centers of Innovation Program and for what it means to us as we conduct leading-edge research. I regard Waters as more than just an instrument vendor; they are a research partner,” said Prof. Rudd.

Prof. Rudd and her team are working with Waters® mass spectrometry based systems to take challenging glycan characterization to the next level.

By improving understanding of glycan chemical and molecular structure, scientists can better understand safety and efficacy profiles for a potential molecule, leading directly to novel biotherapeutic options.

“It’s truly exciting to announce and confirm our collaboration with Pauline and NIBRT,” said Mike Harrington, PhD, Vice President European and Asia Pacific Operations, Waters Division.

Harrington continued, “At Waters we believe in the science of what’s possible, that there are no problems that science cannot solve. We’re lucky to be working with a dedicated partner like NIBRT which believes in the power of science and the importance of research and training.

Biopharmaceuticals are increasingly important to patients and drug manufacturers. By 2014, it is expected that 50% of the top 100 prescribed medications will be biopharmaceuticals, including four of the top five selling drugs.

Ireland’s exports of pharmaceuticals valued at approximately 55 billion Euros now accounts for more than 50% of the country’s GDP.

“In the future most new pharmaceuticals coming on line will be glycoproteins, very large and complex molecules and very challenging to analyze to ensure their safety and efficacy. We’re now moving to a new phase of technical development not only for glycan analysis but for full product characterization. So these wonderful instruments from Waters will help us move the field forward and train the next generation of scientists in glycobiology,” Prof. Rudd said.

In other news, Waters and NIBRT have established the Complete Product and Processing Characterization Facility (CPPCF) for hands-on laboratory based scientific training and retraining of ‘fit-for-purpose’ biopharmaceutical analysis, including protein and peptide characterization.

The CPPCF’s goal is to provide comprehensive training of industry and governmental technicians and scientists to help the burgeoning industry develop advanced biotherapeutic characterization.

The new facility will also educate scientists on existing and upcoming U.S. and European drug regulations.

“The combination of Pauline Rudd’s expertise in glycan analysis and Waters technology for analysis of complex biological samples provides a unique combination of capabilities that can help underpin Ireland’s continued reputation as a centre of excellence for the very highest quality standards in biopharmaceutical manufacturing,” commented Minister Sherlock.

“I’m truly delighted to announce this collaboration as it will surely assist both NIBRT and Waters in further cementing their reputation as providers of choice for the biopharmaceutical industry and Ireland’s reputation as a world leading location for biotech manufacturing.”

He added, “It’s a privilege for me to acknowledge this collaboration, to congratulate Pauline and to see that the collaboration between NIBRT and Waters continues to flourish.”

Waters is the leader in biopharmaceutical analytical technology, which is fundamental to the advancement of biopharmaceuticals.

The company offers a comprehensive technology solution that gives biopharmaceutical manufacturers the analytics they need from discovery to development to commercialization and everything in between.

Waters’ effort with NIBRT is the latest demonstration of the company’s commitment to creating partnerships that enable it to multiply its impact on critical public health issues, including food safety, safe drugs and clean water.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SIMM Honored by Waters Centers of Innovation Program
Research Center for traditional Chinese medicine modernization recognized for advancing quality control authentication and profiling methods.
Wednesday, October 28, 2015
Waters’ Centers of Innovation Program Honors Ohio State University Laboratory
Wysocki-led facility recognized for proteomics, disease research and mass spectrometry excellence.
Wednesday, September 23, 2015
Waters Centers of Innovation Program Honors CSU Laboratory
Proteomics and metabolomics facility recognized for innovation in biological mass spectrometry.
Wednesday, October 29, 2014
Waters Q3 Revenues up 8 Percent
Company reports third quarter sales of $493 million, an increase of 8% versus sales of $457 million in the third quarter of 2013.
Tuesday, October 21, 2014
Waters, Chinese Pharmacopeia Commission Establish Joint Open Laboratory
Located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute, the new facility is over 400m2.
Thursday, July 10, 2014
Waters, Prosolia Exclusive Agreement for DESI Technology for Clinical MS Applications
Prosolia DESI Technology now available on SYNAPT G2 Si and Xevo G2-XS QTof mass spectrometers.
Monday, June 16, 2014
Waters, Omics LLC Partner to Advance Petroleum Sample Analysis
Collaboration Combines the Value of Ion Mobility Mass Spectrometry (IM-MS) and Accurate Mass Information with Petroleomics Data Processing.
Monday, June 16, 2014
Waters ACQUITY UPLC TQD System Receives Chinese FDA Approval
Chinese FDA approves ACQUITY UPLC TQD system for routine diagnostic applications and neonatal metabolites diseases screening.
Thursday, June 05, 2014
Waters ACQUITY QDa Detector Takes Pittcon Editors' Award
Product receives Editors' Silver award for the most innovative product introduced at Pittcon 2014.
Monday, March 10, 2014
Waters Report 8% Revenue Increase
Fourth quarter 2013 sales were $565 million, an increase of 8% compared to sales of $522 million in the fourth quarter of 2012.
Tuesday, January 28, 2014
Waters Teams With Biochemical Society on Proteomics Training Day and Symposium
The consecutive events will take place on March 24 - 27, 2014 in Chester, England.
Wednesday, November 27, 2013
Waters Acquires Nonlinear Dynamics
Nonlinear Dynamics is best known for their Progenesis software which offers researchers unique ways to analyze and visualize the raw proteomic data.
Thursday, August 08, 2013
Waters Sponsors Clinical Chemistry Fellowship
The two-year, postdoctoral fellowship at the University of California, San Diego School of Medicine will emphasize a combination of training in classical clinical chemistry and specialty areas.
Wednesday, July 31, 2013
New Phenome Centre will Decipher Roles of Nature and Nurture in Human Health
The MRC-NIHR Phenome Centre will examine around one hundred thousand blood and urine samples every year, putting the UK at the forefront of a revolution in health and medical research.
Wednesday, June 05, 2013
Waters Users’ Meeting at ASMS 2013
Register for the Waters Users’ meeting at ASMS 2013 and learn about the latest developments in Mass Spectrometry from Waters experts as we reveal our new technologies and solutions.
Monday, May 13, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Acetaldehyde and Formaldehyde Content in Foods
Korean researchers have determined the content of the toxic and carcinogenic aldehydes, acetaldehyde and formaldehyde, in a variety of food groups.
Combining the Power of Mass Spectrometry & Microscopy
A tool that provides world-class microscopy and spatially resolved chemical analysis shows considerable promise for advancing a number of areas of study, including chemical science, pharmaceutical development and disease progression.
Increasing Vitamin D Supplementation
New study from ETH Zurich finds that elderly women should consume more vitamin D than previously recommended during the winter months.
Advancing Lithium-Ion Battery Research
The increasing number of components in a lithium-ion battery makes it essential to use a variety of analytical methods to attain complete characterization.
Clearest Ever Images of Enzyme that Plays Key Roles in Aging, Cancer
UCLA-led research on telomerase could lead to new strategies for treating disease
Fruit Fly Pheromone Flags Great Real Estate for Starting a Family
Finding could aid efforts to control mosquito-borne diseases like malaria by manipulating odorants
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos